• Published on bioRxiv, successfully applied the variational quantum eigensolver (VQE) algorithm to calculate the electronic structure of a tau peptide fragment. • Overcame the exponential limits of existing classical computers, demonstrating the possibility of precise biomolecular energy calculations even on NISQ-era hardware. • Presents a scalable pathway for quantum chemical analysis of complex large protein systems through a fragment-based workflow. [Quantum Biology Society] Quantum computing technology, which overcomes the limitations of classical computers, has been deployed to elucidate the aggregation mechanism of the tau protein, one of the core causes of Alzheimer's disease. By precisely calculating the electronic structure of complex biological systems like peptides at the subatomic level, revolutionary changes are expected in the design of new drugs for treating neurodegenerative diseases in the future. Recently, an empirical study titled "Quantum Computing Reveals Energetics of Tau Peptide Fragments" was published on the preprint repository bioRxiv. A research team led by Dr. Anuj Guruacharya and Dr. Binita Rajbanshi at Nanil Therapeutics Inc. in the USA announced the results of successfully applying a quantum algorithm to a peptide system through this paper. ■ 'Variational Quantum Eigensolver (VQE)' Breaking Through Classical Limits Accurately predicting electron interactions within biomolecules is the core of new drug development, but there has been a fatal problem where the amount of computation required by classical computers increases exponentially as the molecule size grows. To solve this, the research team introduced the variational quantum eigensolver (VQE) algorithm, which can be run even on current noisy intermediate-scale quantum (NISQ) devices. The research team targeted a peptide fragment, which is a core region of the tau protein aggregates observed in the brains of Alzheimer's disease patients, and successfully derived its electronic structure and ground state energy under a quantum environment. ■ Elucidating the Differences Between Electronic Structure Methods and Classical Force Fields One of the greatest achievements of this study is that it rigorously compared and verified the energy calculations from the quantum algorithm against existing classical methods. As a result of the analysis, the quantum energy values from VQE showed systematic agreement with classical restricted Hartree-Fock (RHF) calculations, but exhibited a weak correlation with classical molecular dynamics (MD) force-field energies widely used in conventional drug design. This suggests that classical force-field models have limitations in fully capturing the electronic properties of biomolecules, proving that quantum mechanical treatment is essential for more precise drug design. ■ Securing Fragment-Based Scalability for Macromolecular Protein Analysis Instead of calculating the entire macromolecular protein at once, the researchers integrated a fragment-based workflow into VQE, dividing the molecule into smaller pieces for computation. This approach presents a practical pathway to scale to large systems using current quantum computing resources efficiently, while preserving the essential quantum characteristics of complex biological peptide systems. This empirical study is evaluated as a significant milestone demonstrating how quantum biology theory can be integrated into actual drug development platforms. Experts predict that as this technology advances, ultra-precise peptide drug design and the prediction of complex protein-protein interactions—which were impossible in the past due to computational cost issues—will become possible in near real-time.
• Published on bioRxiv, successfully applied the variational quantum eigensolver (VQE) algorithm to calculate the electronic structure of a tau peptide fragment. • Overcame the exponential limits of existing classical computers, demonstrating the possibility of precise biomolecular energy calculations even on NISQ-era hardware. • Presents a scalable pathway for quantum chemical analysis of complex large protein systems through a fragment-based workflow. [Quantum Biology Society] Quantum computing technology, which overcomes the limitations of classical computers, has been deployed to elucidate the aggregation mechanism of the tau protein, one of the core causes of Alzheimer's disease. By precisely calculating the electronic structure of complex biological systems like peptides at the subatomic level, revolutionary changes are expected in the design of new drugs for treating neurodegenerative diseases in the future. Recently, an empirical study titled "Quantum Computing Reveals Energetics of Tau Peptide Fragments" was published on the preprint repository bioRxiv. A research team led by Dr. Anuj Guruacharya and Dr. Binita Rajbanshi at Nanil Therapeutics Inc. in the USA announced the results of successfully applying a quantum algorithm to a peptide system through this paper. ■ 'Variational Quantum Eigensolver (VQE)' Breaking Through Classical Limits Accurately predicting electron interactions within biomolecules is the core of new drug development, but there has been a fatal problem where the amount of computation required by classical computers increases exponentially as the molecule size grows. To solve this, the research team introduced the variational quantum eigensolver (VQE) algorithm, which can be run even on current noisy intermediate-scale quantum (NISQ) devices. The research team targeted a peptide fragment, which is a core region of the tau protein aggregates observed in the brains of Alzheimer's disease patients, and successfully derived its electronic structure and ground state energy under a quantum environment. ■ Elucidating the Differences Between Electronic Structure Methods and Classical Force Fields One of the greatest achievements of this study is that it rigorously compared and verified the energy calculations from the quantum algorithm against existing classical methods. As a result of the analysis, the quantum energy values from VQE showed systematic agreement with classical restricted Hartree-Fock (RHF) calculations, but exhibited a weak correlation with classical molecular dynamics (MD) force-field energies widely used in conventional drug design. This suggests that classical force-field models have limitations in fully capturing the electronic properties of biomolecules, proving that quantum mechanical treatment is essential for more precise drug design. ■ Securing Fragment-Based Scalability for Macromolecular Protein Analysis Instead of calculating the entire macromolecular protein at once, the researchers integrated a fragment-based workflow into VQE, dividing the molecule into smaller pieces for computation. This approach presents a practical pathway to scale to large systems using current quantum computing resources efficiently, while preserving the essential quantum characteristics of complex biological peptide systems. This empirical study is evaluated as a significant milestone demonstrating how quantum biology theory can be integrated into actual drug development platforms. Experts predict that as this technology advances, ultra-precise peptide drug design and the prediction of complex protein-protein interactions—which were impossible in the past due to computational cost issues—will become possible in near real-time.
ABSTRACT Near-term quantum algorithms such as the variational quantum eigensolver (VQE) have been widely explored for small-molecule electronic structure calculations, yet their relevance for biologically motivated peptide systems remains largely untested. Here, we apply a rigorously controlled, fragment-based VQE workflow to a tau-derived peptide fragment implicated in protein aggregation in Alzheimer’s Disease. Using an identical active space, basis set, and frozen-core treatment, we benchmark VQE electronic energies against classical restricted Hartree-Fock (RHF) calculations and molecular dynamics (MD) force-field energies across an ensemble of peptide conformations. While VQE and active-space RHF energies show systematic agreement within the defined electronic subspace, both exhibit weak correlation with MD-derived energetics, highlighting the fundamentally different physical contributions captured by electronic structure methods and classical force fields. These results demonstrate that NISQ-era quantum chemistry provides complementary, rather than redundant, information relative to classical MD and delineate the scope and limitations of applying VQE to biologically relevant peptide fragments. Our study establishes a disease-motivated benchmark framework for integrating quantum electronic structure calculations with classical simulation approaches in peptide biophysics.
- A study published in the international journal npj Quantum Information (Nature Portfolio) presents a resource-efficient quantum algorithm framework based on the Variational Quantum Eigensolver (VQE) for peptide and protein folding. - By translating protein folding into a tetrahedral lattice model and combining Conditional Value-at-Risk (CVaR) VQE with a classical evolutionary algorithm, the number of required qubits was drastically reduced. - It successfully folded a 7-amino acid neuropeptide using only 9 qubits on actual IBM 20-qubit quantum hardware, demonstrating its practical potential for next-generation drug discovery in the NISQ (Noisy Intermediate-Scale Quantum) era. [Quantum Biology Society] The protein folding problem, which involves predicting the three-dimensional structure of proteins and peptides from their primary amino acid sequence, plays a central role in various applications such as chemistry, biology, and medicine. However, as the sequence lengthens, the number of possible structures to explore explodes exponentially, making it difficult for classical computers to handle its intrinsic NP-hard complexity. Recently, a new quantum algorithm that can efficiently solve this long-standing challenge even on noisy intermediate-scale quantum (NISQ) computers has been developed, drawing the attention of the academic community. The paper titled "Resource-efficient quantum algorithm for protein folding," published in the international journal npj Quantum Information, presents an innovative computing framework for the discovery of next-generation peptide drugs. The research team of Anton Robert and Ivano Tavernelli from IBM Quantum, IBM Research - Zurich in Switzerland successfully led this groundbreaking study. ■ The Meeting of Lattice Models and Qubit Optimization Until now, attempts to introduce quantum computing to protein folding have required an unattainably high number of qubits that current, near-term quantum hardware cannot handle. To solve this, the research team converted protein folding into a tetrahedral lattice model. This model can efficiently depict the growth of a polymer chain while maintaining chemically plausible bond angles. In particular, they adopted a method of adding penalty terms to the Hamiltonian to prevent unphysical amino acid overlaps (e.g., beads occupying the same lattice site). Through this, they succeeded in drastically reducing the number of qubits required for calculation while suppressing the complexity of the algorithm to the level of O(N⁴). ■ Demonstration of Folding on Actual Quantum Hardware This algorithm maximized efficiency by combining CVaR-VQE, a variation of the Variational Quantum Eigensolver (VQE), with a classical Differential Evolution optimizer. Applying this technique, the researchers simulated the folding of the 10-amino acid Angiotensin peptide using only 22 qubits, successfully finding the most stable energy state (native fold). Furthermore, they successfully demonstrated the folding of a 7-amino acid neuropeptide (APRLRFY) using only 9 qubits on IBM's 20-qubit quantum computer hardware. This study is a groundbreaking achievement proving that the protein folding problem, which previously required massive computing resources, can be successfully solved even in a noisy real quantum processor environment. It is expected to bring tremendous innovation to next-generation /de novo/ drug design and disease treatment research utilizing quantum computing in the future.
A study published on the preprint repository arXiv comprehensively outlines empirical applications of quantum algorithms (such as VQE, QAOA) that can be executed on near-term noisy intermediate-scale quantum (NISQ) hardware to solve key challenges in molecular biology and drug discovery, such as protein folding and molecular docking. Through quantum simulations that overcome the limits of classical computing, it was demonstrated that by directly simulating the Hamiltonian of a chemical system, the 3D energy-minimized state of peptides or small molecule compounds can be accurately predicted with significantly fewer computing resources than before. It provides a practical roadmap for combining quantum machine learning (QML) and molecular biology to dramatically reduce massive computational costs and achieve overwhelming efficiency in the next-generation in silico drug discovery process. [Quantum Biology Society] Problems such as protein folding and molecular docking, which cause the biggest bottlenecks in the drug discovery process, become exponentially more complex as the amino acid sequence gets longer. The number of cases to explore explodes, making it difficult for classical computers to handle their NP-hard complexity. Recently, a groundbreaking demonstration framework aiming to introduce the latest quantum computing algorithms into the pharmaceutical and biotechnology fields to overcome these limitations has been presented, drawing attention from the related industry. The paper titled "Quantum computing for molecular biology," published on the preprint repository arXiv, comprehensively covers the application of practical quantum algorithms (e.g., VQE, QAOA) capable of solving drug discovery challenges that have hit the limits of classical computing, using noisy intermediate-scale quantum (NISQ) hardware. A research team including Alberto Baiardi and Markus Reiher from ETH Zurich in Switzerland, along with Matthias Christandl from the University of Copenhagen in Denmark, led this innovative convergent research. ■ Quantum Simulation: Overcoming the Limits of Classical Computing The research team demonstrated that by utilizing the characteristic of quantum computers to efficiently map and directly simulate the Hamiltonian of chemical systems, the complex 3D energy-minimized states of peptides or small molecule compounds can be accurately found with significantly fewer computing resources than before. This is because quantum computers can fundamentally bypass the "curse of dimensionality," where the computational amount expands exponentially, by naturally simulating the quantum mechanical properties of molecules. ■ A Roadmap for Next-Generation Drug Discovery This research goes beyond simply presenting algorithms; it provides a specific roadmap for next-generation in silico drug discovery processes by combining quantum machine learning (QML) and molecular biology. Through this, it has opened a path to achieve overwhelming efficiency by drastically reducing the massive computational costs and time required to screen drug candidates and optimize their most stable binding structures. This practical guide strongly suggests that quantum computing will become a core foundational technology bringing substantial innovation to the life sciences and pharmaceutical industries in the future. https://arxiv.org/abs/2212.12220
Abstract Quantum computing in biology is one of the most rapidly evolving field of technology. Protein folding is one of the key challenges which requires accurate and efficient algorithms with a quick computational time. Structural conformations of proteins with disordered regions need colossal amount of computational resource to map its least energy conformation state. In this regard, quantum algorithms like Variational quantum eigensolver (VQE) are applied in the current research work to predict the lowest energy value of 50 peptides of 7 amino acids each. VQE is initially used to calculate the energy values over which Variational Quantum Optimization is applied via Conditional Value at Risk (CVaR) over 100 iterations of 500000 shots each to obtain least ground state energy value. This is compared to the molecular dynamics-based simulations of 50 nanoseconds each to calculate the energy values along with the folding pattern. The results suggest efficient folding outcomes from CvaR-VQE compared to MD based simulations. With the ever-expanding quantum hardware and improving algorithms the problem of protein folding can be resolved to obtain in depth insights on the biological process and drug design.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
• A study published on arXiv presents a hybrid framework combining VQE, QM/MM, and statistical thermodynamics to predict protein-ligand binding free energies (BFEs) accurately and rapidly. • Explicitly handles polarization, charge redistribution, and electron correlation—often missed by purely classical methods—achieving an outstanding mean absolute error (MAE) of 1.10 kcal/mol. • Reduces computational costs 20-fold compared to conventional alchemical free energy perturbation (FEP) approaches (taking approximately 25 minutes per ligand), establishing a robust foundation for high-throughput lead optimization and future ML-integrated screening. [Quantum Biology Society] Predicting protein-ligand binding free energy (BFE), a core challenge in drug discovery, has long faced a dilemma: increasing accuracy requires massive amounts of computing resources. Traditional high-precision techniques, such as free energy perturbation (FEP), are computationally intensive and difficult to scale for large-scale applications. Recently, a groundbreaking study has been published that breaks through these limitations using a hybrid quantum-classical algorithm based on a variational quantum eigensolver (VQE), reducing computational costs by 20-fold and drawing intense interest from the pharmaceutical industry. ■ Perfect Synergy Between Quantum Mechanics and Statistical Thermodynamics The study titled "Synergistic Computational Approaches for Accelerated Drug Discovery: Integrating Quantum Mechanics, Statistical Thermodynamics, and Quantum Computing," released on the preprint repository arXiv, combines the advantages of classical and quantum computing. A research team led by Farzad Molani and Art E. Cho (from inCerebro and Korea University) designed a new framework that maximizes both computational efficiency and precision. The researchers integrated quantum mechanically refined ligand partial charges and QM/MM interaction evaluations based on the Mining Minima sampling technique. Notably, they added an electronic energy correction step using a variational quantum eigensolver (VQE), significantly boosting precision without compromising efficiency. ■ Overcoming the Blind Spots of Polarization and Electron Correlation The greatest strength of this hybrid model is its ability to explicitly handle effects such as polarization, charge redistribution, and electron correlation, which are frequently underestimated in purely classical scoring systems. By applying this system to 23 protein targets and 543 diverse ligands, the team successfully achieved an excellent MAE of 1.10 kcal/mol along with high fidelity in ranking predictions. ■ 20x Faster Computation: A Cornerstone for Machine Learning (ML) Integration The most encouraging achievement is the overwhelming computational speed. Using standard computing resources, the workflow completed calculations in approximately 25 minutes per ligand, representing a 20-fold reduction in costs compared to traditional FEP methods. The researchers emphasized that this level of accuracy and efficiency is highly suitable for the high-throughput lead optimization process in pharmaceutical drug discovery. Furthermore, this framework is expected to provide an excellent basis for realizing large-scale adaptive predictive screening strategies through seamless integration with future machine learning (ML) models.